Myeloid cells that impair immunotherapy are restored in melanomas which acquire resistance to BRAF inhibitors

Acquired resistance to BRAF(V600E) inhibitors (BRAFi) in melanoma remains a common clinical obstacle, as is the case for any targeted drug therapy that can be developed given the plastic nature of cancers. While there has been significant focus on the cancer cell-intrinsic properties of BRAFi resist...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Cancer Res
Prif Awduron: Steinberg, Shannon M., Shabaneh, Tamer B., Zhang, Peisheng, Martyanov, Viktor, Li, Zhenghui, Malik, Brian T., Wood, Tamara A., Boni, Andrea, Molodtsov, Aleksey, Angeles, Christina V., Curiel, Tyler J., Whitfield, Michael L., Turk, Mary Jo
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2017
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5380540/
https://ncbi.nlm.nih.gov/pubmed/28202513
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-16-1755
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg